Navigation Links
Vasogen Announces 2007 Year-End Results
Date:1/16/2008

MISSISSAUGA, ON, Jan. 16 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), today reported the results of operations for the fiscal year ended November 30, 2007. All dollar amounts referenced herein are in Canadian dollars unless otherwise noted.

At November 30, 2007, our cash and cash equivalents totaled $23.5 million, compared with $30.4 million at November 30, 2006. The change in our cash position resulted mainly from cash used for operations partially offset by cash provided by financing activities. Our net cash used for operations for the three months ended November 30, 2007, was $4.5 million.

The net loss for the fourth quarter of 2007 was $6.1 million, or $0.27 per common share. We incurred a net loss for the year ended November 30, 2007 of $28.8 million, or $1.46 per common share, compared with a net loss of $66.4 million, or $7.05 per common share for the same period in 2006. The key drivers of our reduced losses in 2007 are lower research and development expenses as a result of the completion of our phase III clinical programs in 2006, the corporate costs associated with supporting these programs, and a reduction in expenses associated with our senior convertible notes. These reductions in expenses were partially offset by restructuring costs. The difference between cash used in operations and our accounting loss is driven by non-cash items, such as expenses related to our senior convertible notes and stock options, as well as unrealized foreign exchange gains and losses.

Highlights

- The results from the phase III ACCLAIM trial of our Celacade(TM)

System in patients with chronic heart failure were accepted for

publication in The Lancet, a world-leading medical
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... HealthTronics, Inc ., a leading ... and services, announced that a poster related to ... external beam radiotherapy (EBRT) is being presented at ... (MAAUA) Annual Meeting in Baltimore, Maryland September 18-21, ... and External Beam Radiation as Treatments for Localized ...
(Date:9/18/2014)... 2014 A novel robotic system that ... is currently being tested as part of a biomedical ... Boston with the aim of determining if the robot, ... cancer biopsies faster, more accurate, less costly, and less ... the potential to deliver prostate cancer therapies with greater ...
(Date:9/18/2014)... Station, Texas (PRWEB) September 18, 2014 ... System Chancellor John Sharp, Texas A&M Health Science ... the U.S. Department of Health and Human Services ... today dedicated a national pandemic influenza vaccine manufacturing ... serve as an anchor for the Texas A&M ...
(Date:9/18/2014)... -- Research and Markets has announced ... Report 2014" report to their offering. ... is a professional and in-depth study on the ... The report provides a basic overview of ... chain structure. The N-acetylcysteine market analysis is provided ...
Breaking Biology Technology:HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global N-acetylcysteine Industry Report 2014 2
... Maxygen, Inc. (Nasdaq: MAXY ) that it has ... also known as R7025.,MAXY-alpha is a novel interferon-alpha for ... and is licensed to Roche. Preliminary observations from ... the pharmacodynamic and pharmacokinetic effects of,MAXY-alpha occurred in the ...
... ITMN ) today announced the pricing of its ... stock at a price to the,public of $19.50 per ... purchase up to an additional 525,000 shares of common,stock. ... sold by InterMune. Goldman, Sachs & Co. is ...
... YORK, Sept. 21 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ... to,the Company,s Board of Directors. Mr. Tarnok, 53, ... with extensive pharmaceutical industry experience in a wide,range of ... career at,Pfizer Inc., which he joined in 1989 as ...
Cached Biology Technology:Maxygen Announces Hold on MAXY-alpha Development Program 2Maxygen Announces Hold on MAXY-alpha Development Program 3InterMune Announces Pricing of $68 Million Public Offering of Common Stock 2Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors 2
(Date:9/18/2014)... and nitrogen comprise all spheres of our planet. ... caused imbalances and perturbations that resulted in increases ... result in climate changes which influence the complex ... atmosphere. Understanding these feedback mechanisms has become an ... during the past three decades. , In parallel, ...
(Date:9/18/2014)... that when people are too stressed they are often ... Brain Mind Institute (BMI) at EPFL have just highlighted ... chronic stress and the loss of social skills and ... a synaptic regulatory molecule in the brain. This was ... . , Carmen Sandi,s team went to look ...
(Date:9/18/2014)... probably the ultimate form of camouflage: you don,t just ... strategy is not as uncommon as you might think. ... USA, explains that the larval life stages of many ... of the anatomy that most creatures cannot make transparent. ... to shield each individual eye unit with an opaque ...
Breaking Biology News(10 mins):Greenhouse gas research enters a new era 2How stress tears us apart 2Transparent larvae hide opaque eyes behind reflections 2
... chronic stress day after day can produce wear and tear ... detrimental effect on learning and emotion. However, acute stress ... memory. Researchers at the University at Buffalo have shown, ... stress can produce a beneficial effect on learning and memory, ...
... and their colleagues have identified the gene that is mutated ... paraganglioma (PGL). The gene, called hSDH5, is required for activation ... the chemical reactions that take place within cells to convert ... in the journal Science , to be released online ...
... , , , ... recent analysis of the automated optical inspection (AOI) equipment market, ... & Sullivan Award for Product Innovation of the Year for ... system combines high-speed inspection with superior performance, accuracy, quality, and ...
Cached Biology News:Short stressful events may improve working memory 2Scientists discover gene mutation responsible for hereditary neuroendocrine tumor 2Scientists discover gene mutation responsible for hereditary neuroendocrine tumor 3Frost & Sullivan Recognizes MIRTEC With the 2009 Award for Automated Optical Inspection Product Innovation of the Year 2Frost & Sullivan Recognizes MIRTEC With the 2009 Award for Automated Optical Inspection Product Innovation of the Year 3
... The EC570-90 is a compact, lightweight, high ... 500 volts or 2500 milliamps. It is an ... RNA submarine gels. It is also ideal for ... time can be set to automatically end a ...
Rat Hepatocytes (RH) (>3,000,000 cells)...
QCPN...
Rat Aortic Smooth Muscle Cells (RAOSMC) (>500,000 cells)...
Biology Products: